16-Nov-2023
Noxopharm 2023 AGM Corporate Presentation
16-Oct-2023
Noxopharm talks partnership with Hudson Institute of Medical Research
2-Jun-2023
Noxopharm hails new Sofra™ drug inflammation results
17-Nov-2022
Noxopharm 2022 AGM Corporate Presentation
4-Oct-2022
Ausbiz interview regarding pancreatic cancer research
14-Sep-2022
Noxopharm reveals encouraging new pancreatic cancer preclinical study data
7-Jun-2022
Noxopharm New Corporate Presentation June 2022
25-Mar-2022
Noxopharm CEO talks Veyonda Orphan Drug Designation from US FDA
11-Jan-2022
Noxopharm Presents at HC Wainright BioConnect Conference 10-13 January 2022
22-Dec-2021
Noxopharm Discusses the Subsidiary Pharmorage
17-Nov-2021
Noxopharm 2021 AGM Corporate Presentation
9-Sep-2021
Noxopharm Updated Corporate Presentation
9-Sep-2021
Noxopharm ASX:NOX CEO Dr Graham Kelly on 6PR, 2GB and 3AW Bulls N' Bears
24-Aug-2021
Noxopharm Talks to Proactive Investors about NOXCOVID trial Phase 1 results
11-Aug-2021
Presentation at Proactive Investors Life Sciences Webinar 10 August 2021
5-Jul-2021
Noxopharm Presents at Broker Briefing 1 July 2021
30-Jun-2021
Noxopharm Presents at the Stockhead V-CON Biotech virtual event
28-Jun-2021
Noxopharm Corporate Presentation
20-May-2021
Noxopharm’s CEO Dr Graham Kelly outlines Noxopharm’s ‘Four Pillars’ oncology strategy
27-Apr-2021
CEO Dr Graham Kelly speaks with The Inside Network
23-Apr-2021
Interview with Proactive Investors: Noxopharm CEO encouraged by positive interim data from NOXCOVID trial
7-Apr-2021
Noxopharm (ASX:NOX) CEO Dr Graham Kelly presents to the Switzer Small & Micro Cap Conference March 2021
29-Mar-2021
Corporate Presentation for Switzer Virtual Investor Day
24-Mar-2021
The CEO Masterclass - Noxopharm CEO Dr Graham Kelly speaks with Peter Switzer
18-Mar-2021
Noxopharm Presents to the ASX Small & Mid Cap Conference March 2021
18-Mar-2021
Noxopharm with Proactive Investors at the ASX Small and Mid-Cap Conference March 2021
Noxopharm with Proactive at the ASX Small and Mid-Cap Conference (proactiveinvestors.com.au)
16-Mar-2021
ASX Small-Mid Cap Conference Corporate Presentation
5-Mar-2021
Noxopharm Presents to H.C. Wainwright Global Conference
23-Feb-2021
Noxopharm Updated Corporate Presentation February-March 2021
12-Feb-2021
Noxopharm study finds its drug improves prostate cancer survival rates
1-Feb-2021
Noxopharm (ASX:NOX) - Hidden Gems Webinar Presentation - ShareCafe
28-Jan-2021
Noxopharm To Present to ShareCafe Hidden Gems Webinar
9-Dec-2020
Noxopharm Limited (ASX:NOX) CEO and Managing Director Dr Graham Kelly gives an update on the company and its clinical trials.
8-Dec-2020
Noxopharm Corporate Presentation December Investor Webinar
7-Dec-2020
The Market Herald Deal Room Interview with Noxopharm CEO and Managing Director Dr Graham Kelly
2-Dec-2020
Switzer Small & Micro Cap Virtual Investor Day 2020
17-Nov-2020
Noxopharm 2020 AGM Corporate Update
13-Nov-2020
CEO Dr Graham Kelly discusses the announcement of independent validation of Noxopharm's DARRT cancer therapy with TCN TV
9-Oct-2020
Noxopharm CMO discusses first patient treated in NOXCOVID trial
21-Sep-2020
Noxopharm Corporate Presentation September 2020
19-Aug-2020
Pitt Street Research Noxopharm CEO interview August 2020
14-Aug-2020
Noxopharm August 2020 EGM Corporate Presentation
23-Jul-2020
FNN interview: Noxopharm Discusses Converting Cold Cancer Tumours to Hot Tumours
8-Jul-2020
Reach Markets "Meet the CEO's" Virtual Event July 8, 2020 Recording
8-Jul-2020
Corporate Presentation for the Reach Markets Virtual Event
5-Jun-2020
Webcast Overview of ASCO 2020 Annual Meeting NOX Posters
2-Apr-2020
Updated Noxopharm Virtual Roadshow Corporate Presentation
31-Mar-2020
Noxopharm Virtual Roadshow Corporate Presentation
22-Mar-2020
Veyonda® Mode of Action
27-Feb-2020
Noxopharm Corporate Presentation February 2020
26-Feb-2020
Noxopharm (ASX:NOX) LuPIN trial in prostate cancer
29-Jan-2020
Noxopharm Non-Deal Roadshow Presentation
31-Dec-2019
Veyonda® - Boosting the effectiveness of radiotherapy
20-Dec-2019
DARRT-1 Clinical Data Webinar
3-Dec-2019
NOXOPHARM DARRT-1 Interview Dec 2, 2019
20-Nov-2019
NOX 2019 AGM webcast
20-Nov-2019
Noxopharm 2019 AGM Corporate Presentations
22-Oct-2019
NOX and Nyrada TechKnow Invest Roadshow Presentations
2-Oct-2019
Noxopharm looks at treating prostate cancer with Veyonda® in the LuPIN trial
16-Sep-2019
NOX EGM Chairman's Address and Presentation
28-Aug-2019
CEO Interview: Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment – DARRT-1 Interim Results
9-Aug-2019
Noxopharm (ASX:NOX) 3-year listing anniversary update
7-Aug-2019
Noxopharm August 2019 Corporate Presentation
2-Jul-2019
Oral Presentation interim LuPIN-1 trial results given by Assoc. Professor Louise Emmett at SNMMI 2019 Annual Meeting, Anaheim CA
27-Jun-2019
Noxopharm CEO & CMO Dr Greg van Wyk spoke recently with Karen Jagoda on the Empowered Patient Podcast about the increasing interest in combining therapies to treat prostate cancer as well as cancer types.
6-Jun-2019
Noxopharm Corporate Presentation June 2019
8-May-2019
Switzer Daily: How a biotech company could change cancer treatment
2-May-2019
CEO Interview DARRT Program 6-month Interim Results
28-Mar-2019
Noxopharm Ausbiotech Asia Series March 2019 Presentation
5-Mar-2019
March 2019 Corporate Presentation
26-Feb-2019
FNN - Shaw & Partners Investor Event 26.2.19
6-Feb-2019
St Vincent's Hospital Principal Investigator Discussed LuPIN-1 Study
6-Feb-2019
FNN interview with Nox Chief Medical Officer on Interim Data
27-Nov-2018
2018 Annual General Meeting podcast
21-Nov-2018
NOX 2018 AGM Presentations
21-Aug-2018
Noxopharm (ASX:NOX) Presentation, FNN Investor Event, 15 Aug 2018, Sydney
20-Aug-2018
Noxopharm (ASX:NOX) update on NOX66 and radiotherapy trials
14-Aug-2018
NOX Corporate Presentation FNN-Shaw&Partners Investor Event
7-Jun-2018
Noxopharm Corporate Presentation for Public Briefing
7-May-2018
Noxopharm CEO Interview Updates the Company's Current Research and Development Program
3-May-2018
Noxopharm CEO Interview on near-completed NOX66 chemotherapy trial CEP-1
27-Apr-2018
Noxopharm CEO Interview with FNN on the Company's NOX66 and Radiotherapy Clinical Programs
12-Mar-2018
Corporate Presentation - Post Interim Clinical Data Release
6-Mar-2018
Noxopharm CEO talks to FNN about CEP-1 Clinical Study Interim Data from 2018 TAT Congress in Paris, March 5-7
6-Dec-2017
NOX Open Briefing Corporate Presentation
29-Nov-2017
Noxopharm Limited 2017 AGM Webcast, November 27, 2017
27-Nov-2017
AGM Presentations
6-Nov-2017
EGM Presentations
19-Oct-2017
October 2017 Open Briefing Corporate Presentation
8-Aug-2017
Noxopharm Corporate Presentation for 2017 ASX Growth Series Conference, Singapore August 21
25-Jul-2017
New Corporate Presentation
30-May-2017
New Corporate Presentation
10-Apr-2017
Discovery of Idronoxil-C - NOX CEO explains
10-Apr-2017
FNN Interview with NOX CEO Explaining Idronoxil-C Discovery
28-Feb-2017
ASX The CEO Sessions - ASX Interview
28-Feb-2017
ASX The CEO Sessions February 2017 Presentation
21-Feb-2017
ASX CEO Presentation Feb 2017 slides
15-Feb-2017
Upcoming Events and Presentations
6-Feb-2017
Noxopharm (ASX:NOX) talks clinical trials and applications for ‘NOX66’
22-Nov-2016
November 2016 Corporate Presentation
22-Nov-2016
Corporate Presentation Providing Clinical Program Guidance
20-Oct-2016
Corporate Presentation
1-Jun-2016
Investor Roadshow Presentation